Chromadex Corp reports results for the quarter ended in March - Earnings Summary

Niagen Bioscience

09/05/2024 11:23

* Chromadex Corp  CDXC.OQ  reported a quarterly adjusted
loss of 1
cent​​ per share for the quarter ended in March, higher than the
same quarter last year, when the company reported EPS of -3
cents.  The mean expectation of three analysts for the quarter
was for a loss of 2 cents per share. Wall Street expected
results to range from -3 cents to -1 cents per share.
    * Revenue fell 1.8% to $22.15 million from a year ago;
analysts
expected $23.97 million. 
    * Chromadex Corp's reported EPS for the quarter was a loss
of 1
cent​.
    * The company reported a quarterly loss of $492 thousand.
    * Chromadex Corp shares had risen by 10.1% this quarter and
gained 167.8% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Chromadex Corp is
$6.40 
This summary was machine generated from LSEG data May 9 at 10:23
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.02          -0.01          Beat
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.03          -0.01          Beat
 Jun. 30 2023      -0.04          -0.03          Beat